TABLE 5.
1. | No antibodies or lectins required |
2. | Multiplex capabilities with quantitative analysis |
3. | Ability to obtain detailed glycan structures for biomarker studies |
1. | No antibodies or lectins required |
2. | Multiplex capabilities with quantitative analysis |
3. | Ability to obtain detailed glycan structures for biomarker studies |